FOLD's Q4 earnings miss, but revenues beat estimates on strong Galafold and Pombiliti sales. The company is set to be ...

Amicus Therapeutics Inc.将于周四公布第四季度业绩,这可能是这家罕见病生物技术公司作为独立实体发布的最后几次财报之一,因为 BioMarin Pharmaceutical 对其48亿美元的收购交易将在两周后进行股东投票。

The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two ...

Management reiterated full-year 2025 guidance: total revenue growth of 15% to 22%, Galafold revenue growth of 10% to 15%, and Pombiliti and Opfolda revenue growth of 50% to 65%, all at constant ...

Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions ...

This article was originally published on Quiver News, read the full story. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...

When we last performed an analysis on Amicus in May, its stock was trading where it was now. The stock feels like it has put in a strong technical bottom over the past seven months (above) and better ...

Amicus curiae briefs are deeply woven into the fabric of modern federal appellate practice. Indeed, amici curiae submit briefs in approximately ninety percent of the cases that the United States ...